Evaluation of Femoral Nail GT for treating femur fractures
A Post-Market Clinical Evaluation of the Treatment of Femur Fractures With the Femoral Nail Greater Trochanter (GT) of the T2 Alpha Femur Antegrade GT/PF Nailing System
This study is testing a new type of nail used in surgery to see if it safely helps people with femur fractures heal better over a year.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Stryker Trauma and Extremities Industry-sponsored |
| Locations | 6 sites (Sartell, Minnesota and 5 other locations) |
| Trial ID | NCT04015128 on ClinicalTrials.gov |
What this trial studies
This clinical investigation is a prospective, multi-center evaluation aimed at assessing the safety and efficacy of the Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System in treating femoral fractures. A total of 50 subjects will be enrolled, and the study will compare outcomes to historical controls. The primary endpoint is to confirm non-inferior performance at 12 months, measured by the Lower Extremity Measure (LEM) score. Additionally, the study will assess bone consolidation and report any device-related adverse events over a follow-up period of 12 months.
Who should consider this trial
Good fit: Ideal candidates include males and non-pregnant females aged 18 years or older who require surgical treatment for various types of femoral fractures.
Not a fit: Patients with contraindications to the Femoral Nail GT or those who are not surgical candidates may not benefit from this study.
Why it matters
Potential benefit: If successful, this investigation could provide a more effective treatment option for patients with femur fractures.
How similar studies have performed: Other studies have shown success with similar fixation devices, indicating a potential for positive outcomes in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject is a male or non-pregnant female age 18 years or older at the time of surgery; * Subject is willing and able to give written informed consent and comply with the requirements of this Clinical Investigation Plan; * Subject is intended to be treated with the Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System in accordance with the following legally cleared/ approved Indications for Use: Indications for Use approved Outside of Europe include: * Fixation of subtrochanteric, intertrochanteric, ipsilateral neck/shaft, comminuted proximal femoral shaft fractures * Femoral fixation required as a result of pathological disease * Temporary stabilization of fractures of the femoral shaft ranging from the femoral neck to the supracondylar regions of the femur * Open and closed femoral fractures * Pseudoarthrosis and correction osteotomy * Pathologic fractures, impending pathologic fractures and tumor resections * Ipsilateral femur fractures * Fractures proximal to a total knee arthroplasty * Nonunions and malunions * Fractures involving osteopenic and osteoporotic bone Exclusion Criteria: * Subject is currently enrolled in or plans to enroll in any concurrent drug and/or device clinical investigation that, in the opinion of the Investigator, may confound results; * Per the Investigator, the subject is in poor general health or undergoing any concurrent disease that would place the subject in excessive risk to surgery (i.e. significant circulatory problems, cardiac disease).
Where this trial is running
Sartell, Minnesota and 5 other locations
- St. Cloud Orthopedic Associates, Ltd — Sartell, Minnesota, United States (Completed)
- Reno Orthopedic Clinic — Reno, Nevada, United States (Recruiting)
- New York University — New York, New York, United States (Recruiting)
- UC Health — Cincinnati, Ohio, United States (Completed)
- Regional One Health — Memphis, Tennessee, United States (Recruiting)
- Inova Fairfax Medical Campus — Falls Church, Virginia, United States (Recruiting)
Study contacts
- Study coordinator: Monica Fleeman
- Email: monica.fleeman@stryker.com
- Phone: 251-465-5969
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.